KAY E GERALD 5
5 · INTEGRATED BIOPHARMA INC · Filed Nov 16, 2023
Insider Transaction Report
Form 5
KAY E GERALD
DirectorCEO and President10% Owner
Transactions
- Will/Inheritance
Common Stock
2023-03-20−853,022→ 0 total(indirect: By Trust) - Will/Inheritance
Stock Option (right to buy)
2023-03-20−65,000→ 0 totalExercise: $1.04From: 2022-11-03Exp: 2024-03-20→ Common Stock (65,000 underlying) - Will/Inheritance
Common Stock
2023-03-20−4,299,533→ 0 total - Will/Inheritance
Stock Option (right to buy)
2023-03-20−150,000→ 0 totalExercise: $0.23From: 2020-05-24Exp: 2024-03-20→ Common Stock (150,000 underlying) - Will/Inheritance
Stock Option (right to buy)
2023-03-20−100,000→ 0 totalExercise: $0.72From: 2021-11-04Exp: 2024-03-20→ Common Stock (100,000 underlying) - Will/Inheritance
Stock Option (right to buy)
2023-03-20−100,000→ 0 totalExercise: $0.45From: 2023-11-09Exp: 2023-03-20→ Common Stock (100,000 underlying)
Footnotes (6)
- [F1]Includes (i) 819,628 shares registered to the name of EGK LLC, an entity the Reporting Person was the sole member of and (ii) 16,697 shares held in each of the Riva Grantor Trust and Christina Kay Grantor Trust whereas the Reporting Person was the Trustee.
- [F2]The option vested over three years beginning of the first year anniversary noted herein.
- [F3]Due to the passing of the Reporting Person, the Expiration Date is one year from the date of death.
- [F4]Includes 33,333 shares that were not vested at the time of the Reporting Person's passing.
- [F5]Includes 43,333 shares that were not vested at the time of the Reporting Person's passing.
- [F6]None of the Options were vested at the time of passing of the Reporting Person.